CD248 and neoplasm: Again, in tumor-bearing mice, E3K CAR-T cells persisted and expanded in vivo 5–7 days post-ACT (figure 5C), accompanied by a significant decrease in primary tumor growth and weight at endpoint (figure 5D), a significant increase in tumor necrosis (figure 5E), depletion of endosialin+ pericytes within the tumor stroma (figure 5F) and a trend for decreased metastases in E3K CAR-T cell treated mice (figure 5G).